Abstract:e15005 Background: Recent studies highlight the fundamental roles of PITPNM3 in breast cancer metastasis. PITPNM3 is identified as the functional receptor of CCL18 and promotes breast cancer cell invasion and metastasis by binding with CCL18. Since anti-CCL18 neutralized antibodies shows medium binding affinity which restricts their clinical application, small molecular inhibitors targeting PITPNM3 are needed to be further investigated. Therefore, we identified several first in class small molecular inhibitors potentially targeting PITPNM3 and can inhibit breast cancer metastasis conducted by PITPNM3 activation. Methods: We performed computer-assisted drug design by constructing PITPNM3 homology model, characterizing potential binding pockets and docking preselected high diversity structured small molecule compounds into the static PITPNM3 model. Top 100 small molecules in silico scores were selected and screened through basic experiments. After screening, the anti-metastasis effects of selected compounds were tested through transwell migration and invasion assay. Immunofluorescence and qPCR were applied to confirm the expression of vimentin and CDH1. Western blot were used to clarify the inhibition effects of selected compounds on PITPNM3 signaling pathways. Results: By using homology remodeling, we successfully constructed the PITPNM3(680-920aa) protein model. The PITPNM3(680-920aa) domain is responsible for interacting with PYK2 and phosphorylating PYK2. The phosphorylation of PYK2 conducted by PITPNM3 signaling pathway will lead to metastasis and epithelial-mesenchymal transition (EMT) of breast cancer cells. We then characterized the potential binding pockets of this static model and a druggable site was founded. More than 50K molecules with high diversity were docked into this druggable site and scored through their docking performance. Finally, top 100 scored small molecules were selected. In addition, through 1 rounds of toxicity screening, 1 round of transwell migration assay screening and 1 round of transwell invasion assay screening, 4 small molecules with higher bioactivity is identified and 1 compound with the highest bioactivity as well as docking performance among 50K small molecules is chose. This compound can inhibit CCL18 treatment as well as tumor associated macrophage co-culture mediated migration and invasion. Besides, it can also inhibit the phophorylation of PYK2 and Src without inhibition the expression of PITPNM3. Conclusions: Our findings identify the first-in-class anti-PITPNM3 small molecule inhibitors. These compounds can inhibit PITPNM3 signaling pathway and reverse breast cancer metastasis.

Novel Antibodies Against Glycoprotein Ibα Inhibit Pulmonary Metastasis by Affecting Vwf-Gpibα Interaction

Novel Antibodies Against GPIb Alpha Inhibit Pulmonary Metastasis by Affecting Vwf-Gpib Alpha Interaction

A novel rabbit anti-hepatocyte growth factor monoclonal neutralizing antibody inhibits tumor growth in prostate cancer cells and mouse xenografts

A Humanized Single-Chain Antibody Against Beta 3 Integrin Inhibits Pulmonary Metastasis by Preferentially Fragmenting Activated Platelets in the Tumor Microenvironment

Targeted platelet membrane glycoprotein GPIbalpha monoclonal antibody for inhibiting tumor metastasis and screening method thereof

Tumor metastasis inhibitor of targeted mouse platelet membrane glycoprotein GPIb alpha and identification method of inhibitor

Anti-PITPNM3 small molecular compounds reverse breast cancer metastasis by targeting PITPNM3.

A nanobody against the V-ATPase c subunit inhibits metastasis of 4T1-12B breast tumor cells to lung in mice

Cancer Cell-Derived Von Willebrand Factor Enhanced Metastasis of Gastric Adenocarcinoma

Engineering and Characterization of a Chimeric Anti-platelet Glycoprotein Ibα Monoclonal Antibody and Preparation of Its Fab Fragment

Engineering and Characterization of A Chimeric Anti-Platelet Glycoprotein Ib Alpha Monoclonal Antibody and Preparation of Its Fab Fragment

A Novel Platelet Small-Molecule Agonist Targeting Glycoprotein Ibalpha

Two Novel Monoclonal Antibodies to VWFA3 Inhibit VWF‐collagen and VWF‐platelet Interactions

Inhibition of MCF-7 Breast Cancer Cell-Induced Platelet Aggregation Using a Combination of Antiplatelet Drugs.

Combined inhibition of S100A4 and TIGIT suppresses late-stage breast cancer metastasis to the lung by activating T and NK cells

Production and Characterization of Novel Neutralizing Mabs Against Vwf-A3 Domain, an Inhibitor of Binding of Vwf to Collagen and Influence of Interaction Between Vwf and Platelet GPIbα.

Development,identification and Function Assay of Monoclonal Antibody Against Platelet Membrane Glycoprotein Ib

Anti-Inflammatory Effect of Blocking the Interaction Between Platelet Glycoprotein Ibα and the Leukocyte Integrin Αmβ2.

Modified Heparins Inhibit Integrin Αiibβ3 Mediated Adhesion of Melanoma Cells to Platelets in Vitro and in Vivo

Platelets favor the outgrowth of established metastases

Platelet-Derived Factor V is an Important Determinant of the Metastatic Potential of Circulating Tumor Cells.